ITEMS IN AFP WITH KEYWORD:
Attention Deficit/Hyperactivity Disorder
Sep 1, 2015 Issue
Tricyclic Antidepressants for the Treatment of ADHD in Children and Adolescents [Cochrane for Clinicians]
TCAs, specifically desipramine and nortriptyline (Pamelor), are superior to placebo at reducing ADHD symptoms in the short term (two to six weeks); however, the quality of evidence is low. Increased heart rate and diastolic blood pressure may be noted with treatment.
Apr 1, 2015 Issue
Immediate-Release Methylphenidate for the Treatment of ADHD in Adults [Cochrane for Clinicians]
In adults with ADHD, immediate-release methylphenidate improves symptoms of hyperactivity, impulsiveness, and inattentiveness compared with placebo. Short-term adverse effects such as weight loss and decreased appetite do not appear to be serious. However, larger studies of longer duration are needed to evaluate for cardiovascular outcomes.
Learn how to appropriately evaluate for ADHD and what treatments work for different age groups.
Behavior therapy interventions, such as parent training, are first-line treatment for ADHD in preschool-aged children (three to five years of age). Medication is an option for children with moderate to severe ADHD if behavior therapy has not been effective and if the benefits outweigh the harms.
Aug 15, 2013 Issue
ADHD Interventions in Children Younger Than Six Years [Implementing AHRQ Effective Health Care Reviews]
What are the potential benefits and adverse effects associated with treatments for attention-deficit/hyperactivity disorder (ADHD) in preschool-aged children (younger than six years)?
Jan 1, 2013 Issue
AAP Releases Guideline on Diagnosis, Evaluation, and Treatment of ADHD [Practice Guidelines]
The American Academy of Pediatrics (AAP) first published guidelines on the diagnosis and evaluation of attention-deficit/hyperactivity disorder (ADHD) in 2000, with recommendations for treatment published in 2001. Based on new data collected since then, the AAP released new guidelines in 2011, which...
Sep 1, 2012 Issue
Amphetamines for Attention-Deficit/Hyperactivity Disorder in Adults [Cochrane for Clinicians]
Amphetamines improve ADHD symptom severity but, when compared with placebo, they are associated with increased discontinuation rates because of adverse effects. There does not appear to be a difference among dosages or between the immediate- and sustained-release formulations.
Attention-deficit/hyperactivity disorder in childhood can persist into adulthood in at least 30 percent of patients, with 3 to 4 percent of adults meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., diagnostic criteria. A number of conditions, such as thyroid disease, mood di...
Mar 15, 2011 Issue
ICSI Releases Guideline on Diagnosis and Management of ADHD in Children [Practice Guidelines]
Attention-deficit/hyperactivity disorder (ADHD) is a common condition marked by inattention, hyperactivity, and impulsivity. The Institute for Clinical Systems Improvement (ICSI) has released guideline on diagnosis and management of ADHD in children.
Guanfacine is an effective short-term treatment option for ADHD in children six to 12 years of age. Sedation is a marked problem in many children. Patients should take the medication daily to avoid adverse effects that occur with abrupt discontinuation or when the guanfacine is restarted.